Understanding early HIV infections in Zurich
Characterization of Acute and Recent HIV-1 Infections in Zurich. a Long-term Observational Study: the Zurich Primary HIV Infection Study.
This study looks at how early HIV infections affect people's health and how starting treatment right away can change the course of the disease for those newly diagnosed in Zurich.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Zurich Academic / other |
| Drugs / interventions | cART |
| Locations | 1 site (Zurich) |
| Trial ID | NCT00537966 on ClinicalTrials.gov |
What this trial studies
This observational study aims to characterize factors influencing the course of primary HIV infection (PHI) and how these factors can be affected by PHI. It involves a longitudinal approach, continuously enrolling patients with documented acute or recent HIV-1 infections since 2002. The study focuses on the epidemiology of early HIV infection, the impact of early combination antiretroviral therapy (cART), and aims to inform future research on disease progression, transmission, vaccine development, and new treatment strategies.
Who should consider this trial
Good fit: Ideal candidates include individuals with acute or recent HIV-1 infections, defined by specific clinical and laboratory criteria.
Not a fit: Patients with documented HIV infections established more than 180 days after presumed infection will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of early HIV infections, leading to improved treatment and prevention strategies.
How similar studies have performed: Other studies focusing on early HIV infections have shown promise, indicating that this approach is supported by previous research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: A) acute HIV-1 infection, defined as: * negative or evolving immunoblot in the presence of positive p24 Ag and/or detectable plasma HIV-1 RNA and/or * documented HIV seroconversion within 90 dayswith or with-out symptoms and/or clinical signs of PHI (e.g. acute retro-viral syndrome). B) recent HIV-1 infection, defined as: * documented seroconversion of more than 90 days but within 180 days and/or * evolving immunoblot after unambiguous transmission risk (e.g. iv drug use, sexual contact) within 180 days and/or * documented HIV infection and unambiguous transmission risk (iv drug use, sexual contact) within 180 days and/or * documented HIV infection and possible transmission risk (iv drug use, sexual contact) within the last 180 days after infection AND \< 0.5% fraction of ambiguous nucleotides Exclusion Criteria: • Documented HIV infection, however, established diagnosis more than 180 days after presumed date of infection.
Where this trial is running
Zurich
- University of Zurich — Zurich, Switzerland (Recruiting)
Study contacts
- Principal investigator: Huldrych. Günthard, MD — UniversitaetsSpital Zuerich
- Study coordinator: Huldrych Günthard, MD
- Email: Huldrych.Guenthard@usz.ch
- Phone: +41 (0)44 255 11 11
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.